Ligand Pharmaceuticals (LGND) Current Deferred Tax Assets (2011 - 2015)

Ligand Pharmaceuticals (LGND) reported Current Deferred Tax Assets of $7.5 million for Q3 2015, up 93862.5% sequentially from $8000.0 in Q3 2013.

Ligand Pharmaceuticals (LGND) Current Deferred Tax Assets (2011 - 2015) Analysis & Trends

Ligand Pharmaceuticals (LGND) has 4 years of Current Deferred Tax Assets data on file, last reported at $7.5 million in Q3 2015.

For the quarter ending Q3 2015, Current Deferred Tax Assets changed N/A year-over-year to $7.5 million; the trailing twelve-month figure through Sep 2015 stood at $7.5 million (changed N/A YoY), and the FY2012 full-year result was $8000.0, down 96.62% from the prior year.
Current Deferred Tax Assets improved to $7.5 million in Q3 2015, from $8000.0 in the prior quarter.
In the past five years, Current Deferred Tax Assets ranged from a high of $7.5 million in Q3 2015 to a low of $8000.0 in Q4 2012.
A 4-year average of $1.1 million and a median of $237000.0 in 2011 frame the typical range for Current Deferred Tax Assets.
Peak annual rise in Current Deferred Tax Assets reached 80.15% in 2012, while the deepest fall reached 96.62% in 2012.
Tracing LGND's Current Deferred Tax Assets over 4 years: stood at $237000.0 in 2011, then plunged by 96.62% to $8000.0 in 2012, then changed by 0.0% to $8000.0 in 2013, then soared by 93862.5% to $7.5 million in 2015.
Business Quant data shows LGND's Current Deferred Tax Assets at $7.5 million in Q3 2015, $8000.0 in Q3 2013, and $8000.0 in Q2 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Ligand Pharmaceuticals	6.05 Bn	5.27 Bn	48.45 Mn

Download Data